BTIG reiterates Buy rating on Haemonetics with $84 target
BTIG analyst Marie Thibault has reiterated a Buy rating for Haemonetics, maintaining a price target of $84.

*this image is generated using AI for illustrative purposes only.
BTIG analyst Marie Thibault has reiterated a Buy rating for Haemonetics, maintaining a price target of $84. The rating affirmation signals continued confidence in the company's stock performance potential.
Analyst Rating and Price Target
The research note from BTIG reinforces the positive outlook on Haemonetics. The $84 price target provides a specific benchmark for investors regarding the stock's valuation expectations.
| Firm | Analyst | Rating | Price Target |
|---|---|---|---|
| BTIG | Marie Thibault | Buy | $84 |
What specific catalysts does BTIG expect to drive Haemonetics' stock toward the $84 price target?
How might recent market trends in the medical technology sector impact Haemonetics' growth trajectory?
What are the potential risks or challenges that could hinder Haemonetics from achieving this bullish outlook?

























